Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer

Frontiers in Bioscience

Volumn 16, Issue 1, 2011, Pages 116-130

  Giovannetti, Elisa ^a   Erdem, Lale ^a   Olcay, Efnan ^a   Leon, Leticia G ^a,b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

EGFR; Non small cell lung cancer; Outcome; Polymorphisms; Review; Targeted therapies; Toxicity

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; RASH; REVIEW;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; EXANTHEMA; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955049817     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3679     Document Type: Article

References (96)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 59, 225-249 (2009)
2. Buter J, Giaccone G. Medical treatment of non-smallcell lung cancer. Ann Oncol 16 Suppl 2: ii229-ii232 (2005) (Pubitemid 40908962)
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individuals patients from 52 randomized clinical trials. Br Med J 311, 899-909 (1995)
4. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4, 1087-100 (1998) (Pubitemid 28213318)
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346, 92-98 (2002) (Pubitemid 34438899)
6. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372, 1809-1818 (2008)
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353, 123-132 (2005) (Pubitemid 41058344)
8. Friedrich MJ. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone. J Natl Cancer Inst 101, 1039-41 (2009)
9. Sanford M, Scott LJ. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs 69, 2303-28 (2009)
10. Achille M, Gallegos-Ruiz M, Giaccone G, Soria JC. Response to erlotinib in first-line treatment of non-smallcell lung cancer in a white male smoker with squamous-cell histology. Clin Lung Cancer 8, 214-216 (2006) (Pubitemid 44896395)
11. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall-cell lung cancer. J Natl Cancer Inst 97, 643-655 (2005) (Pubitemid 40812628)
12. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14, 6963-6973 (2008)
13. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloSMed 2:e73 (2005)
14. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17 (2005)
15. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA Jr. Restoring Ecadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66, 944-950 (2006) (Pubitemid 43165962)
16. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007) (Pubitemid 46799492)
17. Zucali PA, Gallegos-Ruiz M, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 19, 1605-1612 (2008)
18. Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumour DNA. Pharmacogenomics 6, 873-877 (2005) (Pubitemid 41724361)
19. Weinberg RA. Cytoplasmic signaling circuitry programs many of the traits of cancer. In: The biology of cancer, Chapter 6. Eds: Garland Science (2006)
20. Miettinen PJ, Berger JE, Meneses J, Meneses J, Phung Y, Pedersen RA, Werb Z, Derynnk R. Epithelial immaturity ad multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337-341 (1995)
21. Jorissen R N, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284, 31-53 (2003) (Pubitemid 36331965)
22. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 37, 9-15 (2001)
23. Arteaga CL. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19, 32s-40s (2001) (Pubitemid 32880077)
24. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (suppl 4), 2-8 (2002) (Pubitemid 34977157)
25. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10, 4227s-4232s (2004) (Pubitemid 38812451)
26. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res12, 5268-5272 (2006) (Pubitemid 44497237)
27. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10, 579-589 (2005) (Pubitemid 41429121)
28. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, Lum BL. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin. Pharmacol 46, 282-290 (2006) (Pubitemid 43260315)
29. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80, 136-145 (2006) (Pubitemid 44160689)
30. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13(12), 3731-3737 (2007) (Pubitemid 46955138)
31. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol 7, 499-507 (2006) (Pubitemid 43779172)
32. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44, 1067-1081 (2005) (Pubitemid 41356392)
33. Bier H, Hoffman T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46, 167-173 (1998) (Pubitemid 28239882)
34. Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira JR. FLEX: A randomized, multicenter, Phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin. Oncol 26, 20 Suppl, abstr 3 (2008)
35. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab,as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 25, 5777-5784 (2007)
36. National Comprehensive Cancer Network (2009) NCCN Clinical Practice Guidelines in Oncology: Nonsmall Cell Lung Cancer V.1.2010
37. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: amulticenter phase 2 study. Cancer 113, 2512-2517 (2008)
38. Romano D, De Braud F, Fogli S, Di Paolo A, Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 22 (8), 420-426 (2001) (Pubitemid 32718634)
39. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999)
40. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 27, 432-437 (2006) (Pubitemid 44051569)
41. Araújo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 12, 201-210 (2007)
42. Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10, 59-68, (2009)
43. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43, 1011-1016 (2007) (Pubitemid 46483039)
44. Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: Is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 28, 597-598 (2007) (Pubitemid 350176603)
45. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 15, 14(6), 1797-1803 (2008) (Pubitemid 351469466)
46. Giovannetti E, Tibaldi C, Falcone A, Danesi R, Peters GJ. Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing. J Clin Oncol [Epub ahead of print] (2010)
47. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br. J Cancer 100, 870-893 (2009)
48. Roetger A, Brandt B, Barnekow A. Competitivedifferential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes. DNA Cell Biol 16, 443-448 (1997) (Pubitemid 27210443)
49. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, Ratain MJ. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65, 46-53 (2005) (Pubitemid 40070794)
50. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4, e125 (2007)
51. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type a transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci USA 91, 10217-10221 (1994) (Pubitemid 24311980)
52. Gebhardt F, Bürger H, Brandt B. Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations-a link between genetics and epigenetics. Histol Histopathol 15, 929-936 (2000) (Pubitemid 30488572)
53. Gebhardt F, Zänker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol chem 274, 13176-13180 (1999)
54. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W, Brandt B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60, 854-857 (2000) (Pubitemid 30129514)
55. Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, Soh J, Asano H, Ichimura K, Aoe K, Aoe M, Kiura K, Shimizu K, Date H. The impact of epidermal growth factor receptor gene status on gefitinibtreated Japanese patients with non-small cell lung cancer. Int J Cancer 120, 1239-1247 (2007)
56. Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small cell lung cancer. Pharmacogenet Genomics 17, 313-319 (2007) (Pubitemid 46608538)
57. Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. The epidermal growth factor receptor intron 1 (CA)n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with gefitinib. Eur J Pharmacol 570, 175-181 (2007) (Pubitemid 47247671)
58. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small cell lung cancer patients treated with gefitinib. Pharmacogenomics J 8(2), 129-138 (2008) (Pubitemid 351411549)
59. Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 67(3), 355-360 (2010)
60. Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 83(3), 477-484 (2008) (Pubitemid 351272637)
61. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 9(3), 581-593 (2010)
62. Ma F, Sun T, Shi Y, Yu D, Tan W, Yang M, Wu C, Chu D, Sun Y, Xu B, Lin D. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 66(1), 114-119 (2009)
63. Dubey S, Stephenson P, Levy DE, Miller JA, Keller SM, Schiller JH, Johnson DH, Kolesar JM; Eastern Cooperative Oncology Group. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 1, 406-412 (2006) (Pubitemid 47181415)
64. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-smallcell lung cancer. J Natl Cancer Inst 96, 1133-1141 (2004) (Pubitemid 39207049)
65. Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25, 2248-2255 (2007) (Pubitemid 46954651)
66. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98, 1533-1535 (2008) (Pubitemid 351652321)
67. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, Bond G, Levine AJ. Detection of functional singlenucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 102, 16297-16302 (2005) (Pubitemid 41688908)
68. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36, 131-137 (2004) (Pubitemid 38174370)
69. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcome in esophageal cancer patients treated with chemotherapy. J Clin Oncol 27, 857-871 (2009)
70. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23, 5235-5246 (2005) (Pubitemid 46224035)
71. Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY, Lin ZZ, Yu CJ, Cheng AL, Yang PC. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 64(3), 346-351 (2009)
72. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26, 1119-1127 (2008)
73. Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Wang HS, Su Y. Epidermal growth factor receptor R497K polymorphism is a favourable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res 13, 3597-3604 (2007) (Pubitemid 46955121)
74. Pitari GM, Zingman LV, Hodgson DM, Alekseev AE, Kazerounian S, Bienengraeber M, Hajnóczky G, Terzic A, Waldman SA. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci USA 100, 2695-2699 (2003) (Pubitemid 36297561)
75. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9, 227-246 (2006) (Pubitemid 44750843)
76. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98, 857-862 (2008) (Pubitemid 351341599)
77. Usuda J, Ohira T, Suga Y, Oikawa T, Ichinose S, Inoue T, Ohtani K, Maehara S, Imai K, Kubota M, Tsunoda Y, Tsutsui H, Furukawa K, Okunaka T, Sugimoto Y, Kato H. Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer. Lung Cancer 58, 296-299 (2007) (Pubitemid 47513247)
78. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6, 432-438 (2007) (Pubitemid 47328313)
79. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98, 1739-1742 (2006) (Pubitemid 44942712)
80. Akasaka K, Kaburagi T, Yasuda S, Ohmori K, Abe K, Sagara H, Ueda Y, Nagao K, Imura J, Imai Y. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol Dec25, [Epub ahead of print] (2009)
81. Lemos C, Giovannetti E, Zucali PA, Santoro A, D'Incecco A, Tibaldi C, Peters GJ. Association of EGFR and ABCG2 polymorphisms with gefitinib toxicity in nonsmall cell lung cancer patients. Proc Am Assoc Cancer Res, abstr 1662 (2010)
82. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27, 4406-4412 (2009)
83. Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, Ciardiello F. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26(25), 3654-3660 (2007) (Pubitemid 46842715)
84. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17), 1757-1765 (2008)
85. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28, 911-917 (2010)
86. Gonçalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, Monges G, Bertucci F, Esterni B, Delpero JR, Turrini O, Lelong B, Viens P, Borg JP, Birnbaum D, Olschwang S, Viret F. A polymorphism in the EGFR extracellular domain is associated with progression-free survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMS Cancer 8, 169 (2008)
87. Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Bisonni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J. Clin Oncol 26 (9), 1427-1434 (2008)
88. Zhao X, Dai W, Zhu H, Zhang Y, Cao L, Ye Q, Lei P, Shen G. Epidermal growth factor (EGF) induces apoptosisin a transfected cell line expressing EGF receptor on its membrane. Cell Biol Int 30, 653-658 (2006) (Pubitemid 44209330)
89. Ali-Osman F, Henderson II JE, Adams B, Antoun G, Friedman H, Reardon D, Roger McClendon R, Bigner DD. Genetic polymorphism of the epidermal growth factor (EGF) gene in glioma patients: Distribution and correlation with survival. Proc Am Assoc Cancer Res 47, abstr 1208 (2006)
90. Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet. Genomics 16, 475-483 (2006) (Pubitemid 43922345)
91. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clinical outcome in epidermal growth factor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol 25(24), 3712-3718 (2007) (Pubitemid 47372612)
92. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56(16), 3666-3669 (1996) (Pubitemid 26272010)
93. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res 10, 3237-3248 (2004) (Pubitemid 38685427)
94. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21, 3940-3947 (2003) (Pubitemid 46606207)
95. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol 58, 1853-1864 (2009)
96. Klinghammer K, Knödler M, Schmittel A, Budach V, Keilholz U, Tinhofer I. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 16, 304-310 (2010)